NYSE Content Update: UiPath Celebrates Five-Year Listing Anniversary at NYSE
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, April 21, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. HSBC...
Getinge Interim Report January-March 2026: Organic growth, strong cash flow and regulatory milestone
GOTHENBURG, Sweden, April 21, 2026 /PRNewswire/ -- "We succeeded in surpassing last year's record-breaking first quarter with organic growth in both net sales and order intake," says Mattias Perjos, President & CEO at Getinge. The medtech company's net sales increased organically by 0.8% while the order intake rose by 3.9% organically. Getinge reports a new record-breaking first quarter despite a...
HKeybio Launches World’s First NHP Hidradenitis Suppurativa Model with High Clinical Consistency to Tackle Global Drug R&D Bottleneck
BOSTON and SUZHOU, China, April 21, 2026 /PRNewswire/ -- HKeybio Tech., a global leader in non-human primate (NHP) experimental animal model research and development, today announced the official launch of the world's first NHP Hidradenitis Suppurativa (HS) model, based on over ten years of research and development involving more than 200 NHP subjects. This model exhibits clinical characteristics highly consistent...
Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW)
Seven abstracts accepted for presentation include data from long-term follow-up studies and a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of ZYMFENTRA® (infliximab-dyyb) Findings emphasize clinical decision-making in long-term management of inflammatory bowel disease (IBD), reinforcing Celltrion's commitment to elevating the standard of care and addressing unmet medical need...
Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics’ CDH17 Autologous CAR‑T Program
Five-year collaboration supports consistent clinical supply for Phase 1A/1B GI cancer study PHILADELPHIA and MELBOURNE, Australia, April 21, 2026 /PRNewswire/ -- Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider and Chimeric Therapeutics (ASX: CHM, "Chimeric" or the "Company"), a leading...
From Molecular Design to Scalable Execution: The Combined Impact of AI and Flow Chemistry
SHANGHAI, April 21, 2026 /PRNewswire/ -- As drug discovery places greater emphasis on practical execution and scalable delivery, flow chemistry is playing an increasingly important role across modern synthesis workflows. At the latest Viva Biotech's series webinar, "AI x Flow Chemistry: From Bench to Business — Academic and Industry Perspectives," Viva Biotech...
Calbee Brings Body Granola to Singapore
Body Granola combines a gut health test with a personalized granola subscription Used by over 50,000 people, the Singapore launch marks the service's first step beyond Japan TOKYO, April 21, 2026 /PRNewswire/ -- Calbee, Inc. ("Calbee") announced today that it will bring Body Granola to Singapore, marking the first time...
Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026
HONG KONG, April 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that positive Phase II results from the COMPASSION-26 study evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, in combination with chemotherapy as first-line treatment for advanced pancreatic ductal adenocarcinoma (PDAC), were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting....
Rznomics Reports Interim Clinical Data for RZ-001 in Hepatocellular Carcinoma at AACR 2026 Demonstrating Encouraging Efficacy and Favorable Safety Profile
– RECIST-based ORR of 38.5% (confirmed) and 46.2% (unconfirmed) – mRECIST-based ORR of 61.5% with a complete response (CR) rate of 23% – No Grade 3 or higher adverse events related to RZ-001 observed – Highlights clinical potential of RNA trans-splicing ribozyme platform technology SEOUL, South Korea, April 21, 2026 /PRNewswire/ --...
Joint Commission International Launches Global Patient Safety Awards to Recognize Innovative Healthcare Practices and Excellence
Nominations open for healthcare organizations, national health authorities around the world that demonstrate improvements in safe, quality patient care OAKBROOK TERRACE, Ill., April 21, 2026 /PRNewswire/ -- Joint Commission International (JCI) today launched the nomination process for its inaugural JCI Global Patient Safety Awards, which aim to recognize excellence in patient safety...
